Table II.

Patient disposition after the start of deferasirox treatment

Disposition, n (%)	Patients (n =185)
Completed	62 (33·5)
Discontinued	123 (66·5)
Adverse events	14 (7·6)
Abnormal laboratory value/test procedure	6 (3·2)
Unsatisfactory therapeutic effect	6 (3·2)
No longer requires study drug	9 (4·9)
Protocol violation	3 (1·6)
Subject withdrew consent	44 (23·8)
Lost to follow-up	17 (9·2)
Administrative problems	10 (5·4)
Death	3 (1·6)
Stopped at end of core	7 (3·8)
Stopped at end of extension 1*	4 (2·2)

^*Completed 3-year extension study before extension was prolonged to 4 years by protocol amendment